Mutant debrisoquine hydroxylation genes in Parkinson's disease
- 25 April 1992
- journal article
- Published by Elsevier BV in The Lancet
- Vol. 339 (8800), 1017-1018
- https://doi.org/10.1016/0140-6736(92)90537-d
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotypePharmacogenetics, 1991
- Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypesPharmacogenetics, 1991
- Metabolism and brain accumulation of tetrahydroisoquinoline (TIQ) a possible parkinsonism inducing substance, in an animal model of a poor debrisoquine metabolizerLife Sciences, 1990
- Oxidative polymorphism of debrisoquine in Parkinson's disease.Journal of Neurology, Neurosurgery & Psychiatry, 1990
- MPTP, the neurotoxin inducing parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylationBiochemical and Biophysical Research Communications, 1987
- DEBRISOQUINE METABOLISM IN PARKINSONIAN PATIENTS TREATED WITH ANTIHISTAMINE DRUGSThe Lancet, 1987
- Environmental Factors in the Etiology of Parkinson's DiseaseCanadian Journal of Neurological Sciences, 1987
- ECOGENETICS OF PARKINSON'S DISEASE: 4-HYDROXYLATION OF DEBRISOQUINEThe Lancet, 1985
- AETIOLOGY OF PARKINSON'S DISEASEThe Lancet, 1983